Risk of disease recurrence and survival in patients with multiple myeloma: A German study group analysis using a conditional survival approach with long-term follow-up of 815 patients
Menée en Allemagne à partir de données portant sur 815 patients atteints d’un myélome multiple, cette étude analyse les facteurs associés à la survie conditionnelle à 5 ans
Résumé en anglais
Background : Unlike the traditional method of overall survival prediction in patients with cancer, conditional survival predicts the survival of patients dynamically throughout the course of disease, identifying how a prognosis evolves over time. Methods : The authors assessed 815 consecutive patients with multiple myeloma through the German Study Group on Multiple Myeloma (Deutsche Studiengruppe Multiples Myelom; DSMM) incentive. Over 10 variables, including patient?specific and multiple myeloma–specific parameters, were analyzed at the time of initial diagnosis and repeatedly during follow?up. The probability of survival for another 5 years was calculated according to disease?related and host?related risks. Multivariate Cox models were used to determine baseline and updated prognostic factors for survival. Results : The median follow?up and overall survival were 10.3 years and 5.1 years, respectively. When comparing 5?year conditional survival probabilities from the data derived at the time of initial diagnosis with those updated over time, substantially differing prognoses were observed when follow?up data were used. Multivariate Cox regression models for cohorts surviving 0 to 5 years demonstrated hazard ratios (HRs) for patients aged <60 years, 60 to 69 years, and >70 years of 1, 1.68, and 3.17, respectively. These HRs for age were found to decline for patients surviving 5 years, as well as for those with advanced stages of disease (II/III) and unfavorable cytogenetics, whereas progressive disease remained an important factor in patients surviving 1 year, 3 years, and 5 years, with HRs of 1.85, 2.11, and 2.14, respectively. Conclusions : To the authors' knowledge, the current study is the first analysis of conditional survival in patients with multiple myeloma using both baseline and follow?up risk parameters, demonstrating that regular risk assessment throughout the course of disease and complete follow?up provide a more reliable conditional survival estimation than baseline assessment alone.
